The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly drug ... to-severe obstructive sleep apnea ...
Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...
MORE: Zepbound leads to more weight loss than Wegovy, Eli Lilly says Obstructive sleep apnea isn’t just an inconvenience, it’s a serious medical condition that impairs breathing and sleep quality.
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication ...